Celladon Gets $53M In Funding
socalTECH
MAY 7, 2012
San Diego-based Celladon , a biopharmaceuticals firm developing a genetically targeted enzyme replacement therapy which helps in the treatment of late-stage, heart failure, has raised $53M in a second close of a funding round, the firm said today. and Venrock. and Venrock.
Let's personalize your content